Abstract: Method for the qualitative and semi-quantitative detection of a ligand in a sample of a medium to be tested, by (1) diluting at least one lyophilized reaction medium in said sample, (2) incubating the sample in order to carry out an immunoenzymatic method, and (3) observing the resulting colouration.

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: 1

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4) alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono (C1-C4) alkylamino or a di(C1-C4) alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.

Abstract: The present invention relates to a process for increasing the egg production and strengthening the eggshells of poultry, which comprises the administration to the animal of at least one bisphosphonic compound chosen from a bisphosphonic acid, a physiologically acceptable salt thereof, hydrates thereof and mixtures thereof.

Abstract: The present invention relates to a stable, nondetergent composition based on fatty acids, in microemulsion form, for administration to humans or animals, comprising: from 5 to 30% by weight of one or more fatty acids with a free carboxylic acid function, as active ingredient; from 5 to 35% by weight of one or more surfactants; from 5 to 30% by weight of one or more C1-C12 alcohols, as cosurfactant; from 5 to 35% by weight of one or more water-soluble compounds with a carbonyl or hydroxyl function; and from 0 to 35% by weight of one or more water-immiscible compounds; the said composition having a pH of less than 6.5.

Abstract: The present invention relates to the use of an active substance selected from the group consisting of tiludronic acid, one of its pharmaceutically acceptable salts, one of its hydrates and mixtures thereof, in the preparation of a medicinal product for preventing and treating osteoporosis in poultry.

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.

Abstract: This invention relates to a method of selecting nonpathogenic bacterial strains capable of binding to the receptor sites for tissue adhesion of pathogenic bacterial strains, comprising the steps consisting in: a) bringing the said receptors into contact in vitro with a bacterial strain to be tested; b) adding an antibody directed against the said receptors, the said antibody being optionally labelled in a detectable manner; c) in the case where the said antibody is itself not labelled in a detectable manner, adding an agent for detecting the antibody; d) detecting the presence of the complex formed between the said antibody and the said receptors.